Your Position:Home>Products>Monoclonals/Polyclonals>Anti-Human Osteoactivin/GPNMB Reference Antibody

Anti-Human Osteoactivin/GPNMB Reference Antibody

  • Cat. No.:RB9THC358016
  • Price:Negotiable
  • Clicks:234

Product Detail

Product Parameters

FormLiquid
Host SpeciesHuman
ClonalityMonoclonal
IsotypeIgG2-kappa
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
Concentration1mg/ml
Endotoxin LevelPlease contact the lab for this information.
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Species ReactivityHuman
TargetNMB, Hematopoietic growth factor inducible neurokinin-1 type, HGFIN, GPNMB, Transmembrane glycoprotein NMB
Storage Buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Expression SystemMammalian Cells
Accession NumberQ14956
BackgroundGlembatumumab (CR011) is a fully human IgG2 monoclonal antibody (mAb) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB, or osteoactivin). It was designed to linke to monomethyl auristatin E (MMAE) via a valine-citrulline enzyme-cleavable linker to act as an antibody-drug conjugate (ADC) termed glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics. Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, who acquired CuraGen in 2009. Development of the ADC was discontinued in April 2018 after missing the primary endpoint of its study and failed to help women with tough-to-treat metastatic triple-negative breast cancers (TNBC) stay both alive and progression-free for longer than Roche Holding AG’s Xeloda (capecitabine).
Alternative NamesCDX-011(DOX), CR011, glembatumumabvedotin(ADC), 1020264-78-1
NoteFor research use only. Not suitable for clinical or therapeutic use.
For Research Use Only. Not for Diagnostic Procedures.

Related Products:
Total 33055 records,Divided into 1653 pages,The 1 pages | First Prev Next Last
Live Chat
  • Tel:
  • WeChat ID: 15898894496
  • Add Message
  • 9:00 AM – 6:00 PM